Pelthos Therapeutics target price cut to $21 from $48
PTHS•Piper Sandler cut its target price for Pelthos Therapeutics to $21 from $48.
Related News
Cellectis swings to Q3 net loss of $61.47 million
CLLS•
First Northern Community Bancorp director Jean-Luc Servat reports acquisition of 300 common shares for $5,049
FNRN•
Financial Times headlines include Nvidia CEO Jensen Huang, Mercedes-Benz and Metro Bank
NVDA•
Hudson Pacific Properties CEO Victor J. Coleman reports acquisition of $182,000 in common shares
HPP•
Japan's Nikkei on track for best week in 5 months despite Nvidia turmoil
EWJ•